FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964709642> ?p ?o ?g. }

• W1964709642 endingPage "1922" @default.
• W1964709642 startingPage "1917" @default.
• W1964709642 abstract "HomeCirculationVol. 126, No. 15Catheter-Assisted Pulmonary Embolectomy Free AccessCase ReportPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCase ReportPDF/EPUBCatheter-Assisted Pulmonary Embolectomy Piotr Sobieszczyk, MD Piotr SobieszczykPiotr Sobieszczyk From the Cardiovascular Division, Vascular Medicine Section and Cardiac Catheterization Laboratory, Brigham and Women's Hospital, Boston, MA. Search for more papers by this author Originally published9 Oct 2012https://doi.org/10.1161/CIRCULATIONAHA.110.963041Circulation. 2012;126:1917–1922IntroductionCase presentation: A 65-year-old man presented to the emergency department after a fall and was diagnosed with a fracture of the right femoral neck. He was scheduled for surgical repair the following day. During positioning for arthroplasty, he developed hypotension, tachycardia, and hypoxia, followed by pulseless electric activity. He was resuscitated and maintained on epinephrine and norepinephrine infusions. A transesophageal echocardiogram revealed a dilated and hypokinetic right ventricle with preserved apical contractility (Figure 1). Massive pulmonary embolism (PE) was suspected. What are the therapeutic options for this critically ill patient?Download figureDownload PowerPointFigure 1. A, A dilated and hypokinetic right ventricle (arrow) is seen on a transesophageal echocardiogram. B, The interatrial septum (arrow) is bulging into the left atrium, suggesting increased right atrial pressure. C, A D-shaped interventricular septum (arrow) is caused by pressure and volume overload of the failing right ventricle. RV indicates right ventricle; LV, left ventricle.Patients afflicted with massive PE have 90-day mortality rates approaching 50%.1 Massive PE is defined by sustained hypotension (systolic blood pressure <90 mm Hg for a minimum of 15 minutes, or requirement for inotropic support), pulselessness, or bradycardia with signs of shock.2 As many as 10% of patients with submassive PE can develop hemodynamically significant and life-threatening right ventricular failure.3 In such cases, supportive care and anticoagulation must be accompanied by rapid reduction of right ventricular (RV) afterload and restoration of adequate cardiac output. Many patients with submassive PE and stable blood pressure develop residual RV dysfunction and experience a decline in functional status at 6-month follow-up. Acute relief of RV strain and reduction of thrombotic burden in the pulmonary arteries could yield long-term benefit in this group.4Pharmacological and invasive strategies for reduction of thrombotic burden in the pulmonary arteries have been used for many decades with variable success.Systemic intravenous thrombolysis has been shown to be of benefit in small trials of patients with massive PE, but it failed to reduce short-term mortality and morbidity in a wide range of patients with submassive PE.5 Thrombolytic therapy is widely available and easy to administer, but these attributes are offset by the obligatory 2-hour infusion, a costly delay when immediate effect is required. Contraindications to systemic thrombolysis are present in as many as 50% of patients,6 and major bleeding complications can occur in 20% of patients,5 further limiting the utility of this therapy. Surgical embolectomy, first conceived by Trendelenburg in 1908 and performed by Kirschner in 1924,7 can be life saving in patients with clot burden in the proximal pulmonary artery (PA). Advances in surgical and anesthesiology techniques have reduced perioperative mortality to 20%,8 but the best outcomes are achieved in a few selected centers with dedicated, rapid-response embolectomy programs.Percutaneous strategies for treatment of massive and submassive PE date back to the development of the Greenfield suction catheter in the 1960s.9 Technical advances in endovascular devices now allow for combining mechanical thrombus disruption and aspiration with pharmacological thrombolysis. This is called pharmacomechanical therapy. Pharmacological therapy allows rapid reduction in RV afterload in patients with hemodynamic instability, whereas mechanical therapy reduces thrombus burden via longer, catheter-directed infusion of a low-dose thrombolytic. There is a growing interest in clinical applications and large-scale investigations of these pharmacomechanical therapies in patients with massive PE and selected patients with submassive PE. This Clinician Update will examine the rationale for catheter-based pulmonary embolectomy and describe endovascular techniques commonly used today.Rationale for Catheter-Assisted Pulmonary EmbolectomyCatheter-based therapies can be rapidly instituted in most medical centers equipped with cardiac and interventional radiology suites in a system akin to one used for treatment of ST-elevation myocardial infarction. Less invasive percutaneous procedures are better tolerated in tenuous patients whose comorbidities frequently preclude consideration of surgical embolectomy. Although many patients cannot tolerate large doses of systemic thrombolysis, catheter-based interventions allow administration of significantly reduced thrombolytic doses directly into the PA. Thrombolytics can be directly infused into the pulmonary circulation at doses that are a fraction of those used for systemic thrombolysis. Tenecteplase and tissue plasminogen activator (tPA) have replaced streptokinase and urokinase as thrombolytics of choice. Over 60% of catheter-assisted interventions include local administration of thrombolytics, which increase clinical success rates.10The disadvantage of endovascular therapies lies in the size mismatch between the caliber of the proximal pulmonary arteries and the size of endovascular devices designed for thrombus removal from much smaller coronary or peripheral vessels or dialysis fistulas. In addition, to be accessible to catheter-assisted embolectomy, the PE has to be located in the main PAs or in the proximal segmental branches. The organized thrombotic cast of a femoral vein lodged in the PA (Figure 2) can be resistant to mechanical techniques developed to deal with fresh and soft thrombus formed on a ruptured atherosclerotic plaque. The addition of prolonged direct infusion of thrombolytic agents is a critical component of these procedures. Even partial mechanical removal and fragmentation of thrombus, however, can be sufficient to restore RV function and reverse circulatory collapse, especially when accompanied by an additional infusion of low dose thrombolytic into the PA (Figure 3).Download figureDownload PowerPointFigure 2. A surgical pulmonary embolectomy specimen shows an organized cast of a femoral vein (arrow) that may be resistant to treatment with a single catheter-based technique.Download figureDownload PowerPointFigure 3. Multiple fragmentation techniques have been used in catheter-based embolectomy procedures. A, A rarely performed balloon angioplasty of venous thrombus in the left pulmonary artery (arrow). B, A pigtail catheter (arrow) manually rotated in the right main pulmonary artery to break up the thrombus. C, An Angiojet rheolytic catheter (arrow) is used to perform thrombectomy in the right pulmonary artery. D, After mechanical fragmentation, infusion catheters are placed in the upper and lower right pulmonary arteries (arrows) to perform catheter-based thrombolysis.Catheter-Assisted Embolectomy TechniquesThe ideal pulmonary embolectomy device would facilitate removal of a large volume of thrombus through small-caliber venous access with exposure to small doses of thrombolytic agents. Because such a device does not exist at present, several hybrid techniques have been developed to restore PA patency (Figure 4).Download figureDownload PowerPointFigure 4. A, A pulmonary angiogram in a patient with massive bilateral PE and multiple filling defects (arrows). B, Repeat angiography after mechanical rheolytic thrombectomy shows improvement in pulmonary perfusion. Restoration of hemodynamic stability allowed additional catheter-directed thrombolysis and further clinical improvement.Catheter-Mediated FragmentationThe expectation that simple disruption and fragmentation of proximal thrombus can restore RV function rests on the premise that the cross-sectional area and volume of more distal PA branches is larger than that of the proximal vessel. Thus, breaking up a large thrombus and redistributing the obstruction into smaller distal branches will reduce the RV afterload and increase the surface area exposed to pharmacological or intrinsic lytic action. This concept was first tested by Brady et al in 199111 who successfully used standard coronary catheters to fragment proximal thrombus in 3 patients with massive PE. An alternative technique described by Schmitz-Rode et al12 involves manual spinning of an angiographic pigtail catheter in the main PA. A long, 80- to-90 cm sheath resting in the proximal PA facilitates advancement of a 100- to 125-cm pigtail catheter over a wire exiting through its proximal side-hole. The shape of the curly pigtail is thus retained as the catheter rotates on a wire like a propeller, churning the thrombus into smaller pieces. Several series have described clinical success with the use of this approach, reporting both angiographic reductions in the degree of obstruction, and hemodynamic improvement, as well.13Fragmentation strategies are particularly effective when combined with thrombolytic infusion directly into the PA.14 Most frequently, fragmentation of the thrombus is accomplished by combining several techniques such as balloon angioplasty, rotational fragmentation, and aspiration of smaller distal fragments with 8F coronary catheters. In clinical practice, delivery of thrombolytic agents can be accomplished by placing multiholed infusion catheters in each affected PA and infusing tPA at 1 to 2 mg/h over a period of 12 to 18 hours. Combined pharmacological and mechanical techniques account for 69% of all catheter-assisted procedures reported over the past decade.10Catheter-Based ThrombectomySeveral devices designed to macerate and simultaneously aspirate thrombus from smaller vessels have been used in the pulmonary arteries. The Aspirex thrombectomy catheter available outside the United States (Straub Medical AG) uses a spiral rotating at 40 000 rpm to fragment the thrombus into smaller particles, which are then aspirated through an adjacent port as the device is advanced and withdrawn through the thrombus. The rotational speed can be adjusted to prevent excessive suction and collapse of the vessel wall around the rotating spiral. Pulmonary application of this device was first described by Kucher et al15 and subsequently shown to be safe and effective in a small clinical series.16 The Amplatz-Helix thrombectomy catheter (eV3, Inc, MN) and the Hydrolyzer catheter (Cordis, NJ) were designed for treatment of thrombosed hemodialysis fistulas. The Helix device uses an impeller spinning at 150 000 rpm to suck in the thrombus, fragment the clot into smaller pieces, and expel the pieces through the side-holes without aspirating them. The device cannot be advanced over a wire, and the clinical experience is quite limited with case series reporting primarily angiographic improvements.17 The Hydrolyzer device uses the Venturi effect to create a vacuum by infusing saline at high pressure as the catheter advances and retreats through the thrombus. This pigtail-tipped catheter is manually rotated and the thrombus fragmented and aspirated. Clinical experience is limited to a few small series.18The largest clinical experience in pulmonary thrombectomy procedures comes from applications of the Angiojet rheolytic thrombectomy catheter (Medrad Interventional, PA). This device relies on the Bernoulli principle to generate a vacuum in the low-pressure zone behind a series of high-pressure saline jets positioned at the tip of the catheter. The saline jets disrupt the thrombus, which is then aspirated in the vacuum zone. A unique feature of this catheter allows forceful spraying of a thrombolytic agent instead of saline without simultaneous aspiration. In this mode, the catheter is advanced through the thrombus, lacing it with 5 to 10 mg of tPA. This pulse-spray treatment facilitates standard thrombectomy performed after a pause of 15 to 30 minutes to allow the thrombolytic agent to take effect. Since the initial description of this device used or treatment of PE by Koning et al in 1997,19 the published experience comprises >140 patients with massive and submassive PE. The largest series included 50 patients with combined catheter-directed thrombolysis used in 30% of treated patients.20 Primary outcome measures have varied from series to series, with mortality ranging from 12% to 25% in a heterogeneous patient population. Its wide application in coronary and peripheral arterial and venous interventions fueled its popularity in PE interventions. When used in the pulmonary and coronary vessels, the release of adenosine from disrupted platelets can lead to bradycardia, pulmonary vasospasm, and worsening hypoxia. These concerns have led to an US Food and Drug Administration black-box warning regarding intrapulmonary interventions with this device. Temporary transvenous pacing and brief treatment runs, and aminophylline administration, as well, can effectively overcome these side effects, allowing successful use of this device with or without thrombolysis.Ultrasound-Assisted TherapiesTraditional catheter -based thrombolysis techniques used catheters with multiple side-holes passively infusing thrombolytic into the thrombosed arterial or venous segment. Ultrasound energy has been shown to disrupt the structure of the thrombus and render it more susceptible to thrombolytic agents. Although high-energy ultrasound can mechanically fragment the clot, lower-energy application dissociates fibrin strands to allow more effective thrombolysis with shorter and lower-dose administration.21 The latter strategy is used by the EKOS device (EkoSonic Endovascular), which combines a catheter with numerous side-holes infusing thrombolytic and a filament with multiple miniature ultrasound transducers. The filament is placed in the catheter's central lumen and emits ultrasound at 2.2 MHz along the treatment zone (Figure 5). This catheter can be used as adjunctive treatment after initial fragmentation or as a standalone strategy of ultrasound-assisted, catheter-directed thrombolysis in more stable patients. Initial experience suggests that 24-hour infusion of tPA at doses <1 mg/h can achieve complete thrombus resolution in 76% of patients and near-complete resolution in an additional 18%.22 Even shorter treatments of 17 hours with mean tPA doses of 0.86 mg/h effectively reduce the Miller score and result in larger thrombus resolution in comparison with higher rates and longer infusions via traditional, passive infusion catheters.23 In a retrospective series of 24 patients with massive and submassive PE, a 12-hour treatment with the EKOS catheter infusing as little as 20 mg of tPA resulted in a statistically significant reduction in the RV to left ventricle ratio.24 Early clinical experience has led to the approval of this device for treatment of PE in Europe where the ongoing randomized ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA) trial (ClinicalTrials.gov Identifier: NCT01166997) will compare outcomes in patients with submassive PE who are treated with the EKOS system versus standard anticoagulation. In the United States, the efficacy of the device will be studied in an industry-sponsored retrospective registry of patients with submassive PE and RV enlargement, and a prospective single-arm trial, as well.Download figureDownload PowerPointFigure 5. Ultrasound-assisted catheter-directed thrombolysis is administered with the aide of the EKOS catheter. A, The console, the catheter with multiple side-holes, and the ultrasound-emitting fiber. B, The catheter is placed in the right and left lung. Note the multiple ultrasound emitters along the length of the catheter (arrow).Suction EmbolectomyThe optimal endovascular intervention would succeed in near-complete removal of pulmonary arterial thrombus without the risk of hemolysis, release of vasoactive agents, or distal embolization. The Greenfield embolectomy catheter aspired to achieve this goal by combining a large-caliber catheter with a suction cup at its end and a syringe to generate suction. Greenfield's early experience showed significant reductions in PA pressures and increase in cardiac output,25 but, despite technical improvements, the catheter remained difficult to use, and its early success could not be replicated. The Angiovac catheter (Vortex Medical) is a modern reiteration of suction embolectomy. The device is approved by US Food and Drug Administration for removal of undesirable vascular debris and consists of a large-caliber catheter with an expandable funnel at its tip that is connected to a circuit resembling a cardiopulmonary bypass system, where a pump generates suction of 3 L/min, filters the blood, and returns it via another catheter. The large caliber size requires either surgical cut-down or a large-bore sheath insertion. The stiff catheter can be difficult to advance to the PA.Complications of Catheter-Based PE InterventionsMany complications of PE interventions are intrinsic to the pulmonary anatomy and are independent of the type of device used. The thin-walled PA branches are prone to perforation, prompting many clinicians to recommend limiting interventions to the main PA and the larger segmental branches of the lower lobes. Perforation can result in pericardial tamponade or life -threatening hemoptysis. Concomitant use of even low doses of thrombolytic agents carries the risk of bleeding complications, but cumulative experience suggests that major procedural complications, including bleeding, can be as low as 2.4%.10 Catheter fragmentation techniques have been reported to cause paradoxical elevation of pulmonary arterial pressures and worsening hemodynamic status, likely via embolization of proximal thrombus into the distal branches.26,27 Some of the complications are device specific. The Angiojet device may be associated with higher rates of periprocedural complications, particularly bradycardia and hemoglobinuria.10 There is, however, no head-to-head comparison of the various endovascular techniques to assess their relative safety.Challenges and Future DirectionsCatheter-assisted, pharmacomechanical pulmonary thrombectomy has not been rigorously studied as a viable treatment strategy. This is largely because of low interest in treating venous thromboembolic disease among cardiovascular specialists, complex and heterogeneous patient groups who experience PE, and lack of an optimal percutaneous device to treat the large volume of organized thrombus in the pulmonary arteries. None of the devices or catheters commonly used today are approved by the US Food and Drug Administration. Numerous combinations of endovascular techniques have been described in small clinical series, but few have used uniform outcome metrics, reliably differentiated between massive and submassive PE, or compared devices with each other, with surgical embolectomy, or with medical therapy.The cumulative contemporary experience in patients with massive PE comprises ≈35 predominantly retrospective series totaling 594 patients and suggests that catheter-assisted therapies are safe and lead to hemodynamic resolution of hypoxia and survival to hospital discharge in as many as 86% of patients with massive PE.10 Optimal use of catheter-assisted embolectomy in these patients demands the introduction of a system capable of rapid diagnosis, triage, and treatment in a manner mirroring the treatment of patients with ST-segment elevation myocardial infarction. Rigorous prospective data are needed to standardize endovascular therapy and determine patient subgroups that may benefit from endovascular therapy as opposed to systemic thrombolysis.The growing experience in the endovascular treatment of PE demands a concerted effort toward a systematic and prospective evaluation of these therapies to determine which strategies are most beneficial and which patients benefit the most.Case ResolutionThis patient was immediately transferred to the cardiac catheterization laboratory. Pulmonary angiography revealed thrombus occluding the right and left lower lobe pulmonary arteries. Pulmonary artery pressure was elevated at 47/13 mm Hg. Pulse-spray thrombectomy with the use of the Angiojet catheter resulted in significant resolution of the thrombus. Pulmonary artery pressure decreased to 30/15 mm Hg, and inotropic support was discontinued. Additional catheter-directed thrombolysis was performed in each lung with a low dose of tPA over the course of 18 hours. A retrievable inferior vena cava filter was placed in anticipation of hip surgery. He was extubated the following day. Successful open reduction and internal fixation of the hip was performed 6 days later. He was discharged to a rehabilitation facility on warfarin therapy without the need for supplemental oxygen.Endovascular therapy was chosen over surgical embolectomy because it could be rapidly implemented in this patient in extremis. Systemic thrombolysis was deemed to be relatively contraindicated because of the risk of bleeding at the site of hip fracture. This clinical case highlights some of the advantages of catheter-based interventions: rapid initiation of therapy, very low doses of adjunctive thrombolytic therapy, and the expectation of rapid hemodynamic improvement in patients with an acute thrombotic event. The choice among the 3 treatment modalities should depend on local expertise, patient characteristics, and the speed with which they can be applied.DisclosuresNone.FootnotesCorrespondence to Piotr Sobieszczyk, MD, Cardiovascular Division, Vascular Medicine Section and Cardiac Catheterization Laboratory, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail [email protected]orgReferences1. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive pulmonary embolism. Circulation. 2006; 113: 577–582.LinkGoogle Scholar2. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BKAmerican Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and ResuscitationAmerican Heart Association Council on Peripheral Vascular DiseaseAmerican Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011; 123: 1788–1830.LinkGoogle Scholar3. Stein PD, Matta F, Janjua M, Yaekoub AY, Jaweesh F, Alrifai A. Outcome in stable patients with acute pulmonary embolism who had right ventricular enlargement and/or elevated levels of troponin I. Am J Cardiol. 2010; 106: 558–563.CrossrefMedlineGoogle Scholar4. Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest. 2009; 136: 1202–1210.CrossrefMedlineGoogle Scholar5. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347: 1143–1150.CrossrefMedlineGoogle Scholar6. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD, Rauber K, Iversen S, Redecker M, Kienast J. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997; 30: 1165–1171.CrossrefMedlineGoogle Scholar7. Kirschner M. Ein durch die Trendelenburgsche Operation Geheilter Fall von Embolie der Art. Pulmonalis Arch Klin Chir. 1924; 133: 312–359.Google Scholar8. Stein PD, Alnas M, Beemath A, Patel NR. Outcome of pulmonary embolectomy. Am J Cardiol. 2007; 99: 421–423.CrossrefMedlineGoogle Scholar9. Greenfield LJ, Kimmell GO, McCurdy WC. Transvenous removal of pulmonary emboli by vacuum-cup catheter technique. J Surg Res. 1969; 9: 347–52.CrossrefMedlineGoogle Scholar10. Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009; 20: 1431–1440.CrossrefMedlineGoogle Scholar11. Brady AJ, Crake T, Oakley CM. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolus. Lancet. 1991; 338: 1186–1189.CrossrefMedlineGoogle Scholar12. Schmitz-Rode T, Gunther RW, Pfeffer JG, Neuerburg JM, Geuting B, Biesterfeld S. Acute massive pulmonary embolism: use of a rotatable pigtail catheter for diagnosis and fragmentation therapy. Radiology. 1995; 197: 157–162.CrossrefMedlineGoogle Scholar13. Schmitz-Rode T, Janssens U, Schild HH, Basche S, Hanrath P, Gunther RW. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest. 1998; 114: 1427–1436.CrossrefMedlineGoogle Scholar14. Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Gunther RW. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol. 2000; 36: 375–380.CrossrefMedlineGoogle Scholar15. Kucher N, Windecker S, Banz Y, Schmitz-Rode T, Mettler D, Meier B, Hess OM. Percutaneous catheter thrombectomy device for acute pulmonary embolism: in vitro and in vivo testing. Radiology. 2005; 236: 852–858.CrossrefMedlineGoogle Scholar16. Popovic P, Bunc M. Massive pulmonary embolism: percutaneous emergency treatment using an Aspirex thrombectomy catheter. Cardiovasc Interv Radiol. 2010; 33: 1052–1055.CrossrefMedlineGoogle Scholar17. Müller-Hülsbeck S, Brossmann J, Jahnke T, Grimm J, Reuter M, Bewig B, Heller M. Mechanical thrombectomy of major and massive pulmonary embolism with use of the Amplatz thrombectomy device. Invest Radiol. 2001; 36: 317–322.CrossrefMedlineGoogle Scholar18. Reekers JA, Baarslag HJ, Koolen MG, Van Delden O, van Beek EJ. Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol. 2003; 26: 246–250.CrossrefMedlineGoogle Scholar19. Koning R, Cribier A, Gerber L, Eltchaninoff H, Tron C, Gupta V, Soyer R, Letac B. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation. 1997; 96: 2498–2500.LinkGoogle Scholar20. Chechi T, Vecchio S, Spaziani G, Giuliani G, Giannotti F, Arcangeli C, Rubboli A, Margheri M. Rheolytic thrombectomy in patients with massive and submassive acute pulmonary embolism. Catheter Cardiovasc Interv. 2009; 73: 506–513.CrossrefMedlineGoogle Scholar21. Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost. 1997; 78: 1063–1068.CrossrefMedlineGoogle Scholar22. Chamsuddin A, Nazzal L, Kang B, Best I, Peters G, Panah S, Martin L, Lewis C, Zeinati C, Ho JW, Venbrux AC. Catheter-directed thrombolysis with the Endowave system in the treatment of acute massive pulmonary embolism: a retrospective multicenter case series. J Vasc Interv Radiol. 2008; 19: 372–376.CrossrefMedlineGoogle Scholar23. Lin PH, AS , Bechara CF, Athamneh H, Weakley SM, Kobayashi K, Kougias P. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. Vascular. 2009; 17: S137.CrossrefMedlineGoogle Scholar24. Engelhardt TC, Taylor AJ, Simprini LA, Kucher N. Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism. Thromb Res. 2011; 128: 149–154.CrossrefMedlineGoogle Scholar25. Greenfield LJ, Proctor MC, Williams DM, Wakefield TW. Long-term experience with transvenous catheter pulmonary embolectomy. J Vasc Surg. 1993; 18: 450–458.CrossrefMedlineGoogle Scholar26. Nakazawa K, Tajima H, Murata S, Kumita SI, Yamamoto T, Tanaka K. Catheter fragmentation of acute massive pulmonary thromboembolism: distal embolisation and pulmonary arterial pressure elevation. Br J Radiol. 2008; 81: 848–854.CrossrefMedlineGoogle Scholar27. Kumar N, Janjigian Y, Schwartz DR. Paradoxical worsening of shock after the use of a percutaneous mechanical thrombectomy device in a postpartum patient with a massive pulmonary embolism. Chest. 2007; 132: 677–679.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Burton J, Madhavan M, Finn M, Ingrassia J, Bikdeli B, Nabavi Nouri S, Brailovsky Y, Rosenzweig E, Takeda K, Green P, Kirtane A, Parikh S and Sethi S (2021) Advanced Therapies for Acute Pulmonary Embolism: A Focus on Catheter-Based Therapies and Future Directions, Structural Heart, 10.1080/24748706.2020.1853860, 5:2, (103-119), Online publication date: 1-Mar-2021. Lakshminarasimhachar A (2021) Anesthetic Management of Minimally Invasive Pulmonary Thrombo-embolectomy Anaesthesia for Uncommon and Emerging Procedures, 10.1007/978-3-030-64739-1_40, (401-415), . Kay D, Madjarov J and Tenny B (2019) Case report: Re-emerging significance of surgical embolectomy in pulmonary embolism, Annals of Medicine and Surgery, 10.1016/j.amsu.2018.11.010, 39, (26-28), Online publication date: 1-Mar-2019. Salsamendi J and Kably I (2019) New Concepts in the Management of Pulmonary Embolus Atlas of Endovascular Venous Surgery, 10.1016/B978-0-323-51139-1.00015-2, (381-396), . Yamaguchi J, Hara N, Yamaguchi T, Nagata Y, Nozato T and Miyamoto T (2017) Successful treatment of a massive pulmonary embolism using rivaroxaban in a patient with antithrombin III deficiency, Journal of Cardiology Cases, 10.1016/j.jccase.2017.06.008, 16:5, (144-147), Online publication date: 1-Nov-2017. Jarrett H and Bashir R (2017) Interventional Management of Venous Thromboembolism: State of the Art, American Journal of Roentgenology, 10.2214/AJR.16.17064, 208:4, (891-906), Online publication date: 1-Apr-2017. Zuin M and Roncon L (2016) Systemic thrombolysis in acute pulmonary embolism: also a matter of “time”, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-016-1444-2, 43:2, (279-282), Online publication date: 1-Feb-2017. Torok R, Fleming G and Hill K (2015) Transcatheter pulmonary embolectomy after fontan, Catheterization and Cardiovascular Interventions, 10.1002/ccd.26096, 87:5, (939-944), Online publication date: 1-Apr-2016. Davies M and El-Sayed H (2016) Current Status of Clot Removal for Acute Pulmonary Embolism, Annals of Vascular Surgery, 10.1016/j.avsg.2015.08.002, 31, (211-220), Online publication date: 1-Feb-2016. Bayram B, Oray N, Korkmaz E, Erdost H and Gokmen N (2014) Massive pulmonary embolism and cardiac arrest; thrombolytic therapy in a patient with recent intracranial surgery and glioblastoma multiforme, The American Journal of Emergency Medicine, 10.1016/j.ajem.2014.04.022, 32:11, (1441.e1-1441.e3), Online publication date: 1-Nov-2014. Clark D, McGiffin D, Dell’Italia L and Ahmed M (2013) Submassive Pulmonary Embolism, Circulation, 127:24, (2458-2464), Online publication date: 18-Jun-2013. Dixon S and Safian R (2013) The Year in Interventional Cardiology, Journal of the American College of Cardiology, 10.1016/j.jacc.2013.01.040, 61:15, (1637-1652), Online publication date: 1-Apr-2013. October 9, 2012Vol 126, Issue 15 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.110.963041PMID: 23044608 Originally publishedOctober 9, 2012 Keywordsthrombus aspirationpulmonary embolismthrombolysisthromboembolismPDF download Advertisement SubjectsCatheter-Based Coronary and Valvular InterventionsPulmonary HypertensionThrombosis" @default.
• W1964709642 created "2016-06-24" @default.
• W1964709642 creator A5038386453 @default.
• W1964709642 date "2012-10-09" @default.
• W1964709642 modified "2023-10-06" @default.
• W1964709642 title "Catheter-Assisted Pulmonary Embolectomy" @default.
• W1964709642 cites W1969276777 @default.
• W1964709642 cites W1971880965 @default.
• W1964709642 cites W1990888709 @default.
• W1964709642 cites W2002821499 @default.
• W1964709642 cites W2025051267 @default.
• W1964709642 cites W2025322364 @default.
• W1964709642 cites W2039064544 @default.
• W1964709642 cites W2041400186 @default.
• W1964709642 cites W2045570267 @default.
• W1964709642 cites W2047267403 @default.
• W1964709642 cites W2048903171 @default.
• W1964709642 cites W2050022728 @default.
• W1964709642 cites W2053661509 @default.
• W1964709642 cites W2055171874 @default.
• W1964709642 cites W2058146270 @default.
• W1964709642 cites W2069080267 @default.
• W1964709642 cites W2075776825 @default.
• W1964709642 cites W2085984247 @default.
• W1964709642 cites W2107941853 @default.
• W1964709642 cites W2108490506 @default.
• W1964709642 cites W2131586360 @default.
• W1964709642 cites W2158250530 @default.
• W1964709642 cites W2164452840 @default.
• W1964709642 cites W2320326518 @default.
• W1964709642 cites W86398073 @default.
• W1964709642 doi "https://doi.org/10.1161/circulationaha.110.963041" @default.
• W1964709642 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23044608" @default.
• W1964709642 hasPublicationYear "2012" @default.
• W1964709642 type Work @default.
• W1964709642 sameAs 1964709642 @default.
• W1964709642 citedByCount "17" @default.
• W1964709642 countsByYear W19647096422012 @default.
• W1964709642 countsByYear W19647096422013 @default.
• W1964709642 countsByYear W19647096422014 @default.
• W1964709642 countsByYear W19647096422015 @default.
• W1964709642 countsByYear W19647096422016 @default.
• W1964709642 countsByYear W19647096422017 @default.
• W1964709642 countsByYear W19647096422019 @default.
• W1964709642 countsByYear W19647096422021 @default.
• W1964709642 countsByYear W19647096422022 @default.
• W1964709642 countsByYear W19647096422023 @default.
• W1964709642 crossrefType "journal-article" @default.
• W1964709642 hasAuthorship W1964709642A5038386453 @default.
• W1964709642 hasBestOaLocation W19647096421 @default.
• W1964709642 hasConcept C141071460 @default.
• W1964709642 hasConcept C164705383 @default.
• W1964709642 hasConcept C2776265017 @default.
• W1964709642 hasConcept C2776652129 @default.
• W1964709642 hasConcept C2781267111 @default.
• W1964709642 hasConcept C71924100 @default.
• W1964709642 hasConceptScore W1964709642C141071460 @default.
• W1964709642 hasConceptScore W1964709642C164705383 @default.
• W1964709642 hasConceptScore W1964709642C2776265017 @default.
• W1964709642 hasConceptScore W1964709642C2776652129 @default.
• W1964709642 hasConceptScore W1964709642C2781267111 @default.
• W1964709642 hasConceptScore W1964709642C71924100 @default.
• W1964709642 hasIssue "15" @default.
• W1964709642 hasLocation W19647096421 @default.
• W1964709642 hasLocation W19647096422 @default.
• W1964709642 hasOpenAccess W1964709642 @default.
• W1964709642 hasPrimaryLocation W19647096421 @default.
• W1964709642 hasRelatedWork W1976670898 @default.
• W1964709642 hasRelatedWork W2022299179 @default.
• W1964709642 hasRelatedWork W2090304485 @default.
• W1964709642 hasRelatedWork W2322726978 @default.
• W1964709642 hasRelatedWork W2417370345 @default.
• W1964709642 hasRelatedWork W2419139487 @default.
• W1964709642 hasRelatedWork W2475264243 @default.
• W1964709642 hasRelatedWork W3109567819 @default.
• W1964709642 hasRelatedWork W3156484997 @default.
• W1964709642 hasRelatedWork W4288518460 @default.
• W1964709642 hasVolume "126" @default.
• W1964709642 isParatext "false" @default.
• W1964709642 isRetracted "false" @default.
• W1964709642 magId "1964709642" @default.
• W1964709642 workType "article" @default.